Angeles Secord

Overview:

My primary research interest has focused on angiogenesis, molecular signatures, clinical trial development, and ovarian cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically on anti-angiogenic therapy and molecular tumor signatures to direct therapy in patients with ovarian cancer to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian, and cervical cancers as well as for benign gynecologic conditions.

Positions:

Professor of Obstetrics and Gynecology

Obstetrics and Gynecology, Gynecologic Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 1994

University of Washington

Resident, Obstetrics & Gynecology

Duke University

Grants:

NCI National Clinical Trials Network U10 (Year 5)

Administered By
Duke Cancer Institute
Awarded By
National Institutes of Health
Role
Co-Principal Investigator
Start Date
End Date

Women with BRCA-mutated Advanced Stage Ovarian Cancer

Administered By
Duke Clinical Research Institute
Awarded By
AstraZeneca LP
Role
Co Investigator
Start Date
End Date

Assessing the relevance of weighted values in the ASCO value framework in ovarian cancer patients

Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Awarded By
Gynecologic Oncology Group
Role
Investigator
Start Date
End Date

Predictive value of the IL6 pathway to direct anti-angiogenic therapy in advanced ovarian cancer

Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Awarded By
American Association of Obstetricians and Gynecologists Foundation
Role
Principal Investigator
Start Date
End Date

Biomarker Discovery to Direct Bevacizumab Therapy in Ovarian Cancer - Blood-based Angiome Profiling

Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Awarded By
National Institutes of Health
Role
Principal Investigator
Start Date
End Date

Publications:

Just OK is not OK: How well does PARP inhibitor frontline maintenance therapy need to work in biomarker negative ovarian cancer for universal treatment to represent a value-based therapeutic option?

Authors
Gonzalez, R; Havrilesky, LJ; Secord, AA; Myers, ER; Dottino, JA; Moss, HA
MLA Citation
Gonzalez, R., et al. “Just OK is not OK: How well does PARP inhibitor frontline maintenance therapy need to work in biomarker negative ovarian cancer for universal treatment to represent a value-based therapeutic option?Gynecologic Oncology, vol. 159, Elsevier BV, 2020, pp. 21–22. Crossref, doi:10.1016/j.ygyno.2020.06.043.
URI
https://scholars.duke.edu/individual/pub1467248
Source
crossref
Published In
Gynecologic Oncology
Volume
159
Published Date
Start Page
21
End Page
22
DOI
10.1016/j.ygyno.2020.06.043

Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress HER2/Neu (NCT01367002): Updated survival analysis

Authors
Fader, AN; Roque, DM; Siegel, ER; Buza, N; Hui, P; Havrilesky, LJ; Secord, AA; O'Malley, DM; Backes, FJ; Nevadunsky, NS; Chambers, SK; Edraki, B; Celano, P; Bellone, S; Azodi, M; Ratner, ES; Litkouhi, B; Silasi, DA; Schwartz, PE; Santin, AD
MLA Citation
URI
https://scholars.duke.edu/individual/pub1467407
Source
crossref
Published In
Gynecologic Oncology
Volume
159
Published Date
Start Page
7
End Page
8
DOI
10.1016/j.ygyno.2020.06.014

Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.

BACKGROUND: Successfully combining targeted agents with chemotherapy is an important future goal for cancer therapy. However, an improvement in patient outcomes requires an enhanced understanding of the tumor biomarkers that predict for drug sensitivity. NRG Oncology/Gynecologic Oncology Group (GOG) Study GOG-86P was one of the first attempts to combine targeted agents (bevacizumab or temsirolimus) with chemotherapy in patients with advanced endometrial cancer. Herein we performed exploratory analyses to examine the relationship between mutations in TP53, the most commonly mutated gene in cancer, with outcomes on GOG-86P. METHODS: TP53 mutational status was determined and correlated with progression-free survival (PFS) and overall survival (OS) on GOG-86P. RESULTS: Mutations in TP53 were associated with improved PFS and OS for patients that received bevacizumab as compared to temsirolimus (PFS: HR 0.48, 95% CI 0.31, 0.75; OS: HR: 0.61, 95% CI 0.38, 0.98). By contrast, there was no statistically significant difference in PFS or OS between arms for cases with WT TP53. CONCLUSIONS: This exploratory study suggests that combining chemotherapy with bevacizumab, but not temsirolimus, may enhance PFS and OS for patients whose tumors harbor mutant p53. These data set the stage for larger clinical studies evaluating the potential of TP53 mutational status as a biomarker to guide choice of treatment for endometrial cancer patients. Clintrials.gov: NCT00977574.
Authors
Leslie, KK; Filiaci, VL; Mallen, AR; Thiel, KW; Devor, EJ; Moxley, K; Richardson, D; Mutch, D; Secord, AA; Tewari, KS; McDonald, ME; Mathews, C; Cosgrove, C; Dewdney, S; Casablanca, Y; Jackson, A; Rose, PG; Zhou, X; McHale, M; Lankes, H; Levine, DA; Aghajanian, C
MLA Citation
Leslie, Kimberly K., et al. “Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.Gynecol Oncol, vol. 161, no. 1, Apr. 2021, pp. 113–21. Pubmed, doi:10.1016/j.ygyno.2021.01.025.
URI
https://scholars.duke.edu/individual/pub1473639
PMID
33541735
Source
pubmed
Published In
Gynecol Oncol
Volume
161
Published Date
Start Page
113
End Page
121
DOI
10.1016/j.ygyno.2021.01.025

A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma

Authors
Duska, LR; Petroni, G; Brown, J; Jelovac, D; Moore, KN; McGuire, WP; Darus, CJ; Barroilhet, LM; Secord, AA
MLA Citation
URI
https://scholars.duke.edu/individual/pub1467408
Source
crossref
Published In
Gynecologic Oncology
Volume
159
Published Date
Start Page
15
End Page
15
DOI
10.1016/j.ygyno.2020.06.028

Targeting family genomic alterations in gynecological malignancies

Authors
Gay, L; Schink, JC; Wright, JD; Lele, SB; Mayor, PC; Odunsi, K; Hemmerich, A; Ngo, N; Secord, AA; Hou, JY; Konecny, GE; Santin, AD; Elvin, JA
MLA Citation
Gay, L., et al. “Targeting family genomic alterations in gynecological malignancies.” Gynecologic Oncology, vol. 154, Elsevier BV, 2019, pp. 89–89. Crossref, doi:10.1016/j.ygyno.2019.04.210.
URI
https://scholars.duke.edu/individual/pub1467401
Source
crossref
Published In
Gynecologic Oncology
Volume
154
Published Date
Start Page
89
End Page
89
DOI
10.1016/j.ygyno.2019.04.210